Sahajanand Medical Technologies’ (SMT) TAVR product Hydra’s 5-year follow-up results from the pivotal Hydra CE Study were presented by Dr. Vilhelmas Bajoras at PCR London Valves 2025. The long-term data reaffirm Hydra’s durable valve performance, sustained hemodynamic improvement, and favourable safety profile in patients with
Study Synopsis In patients classified as HBR, there was a significant reduction in the primary endpoint (p=0.043) when comparing physiology-guided complete revascularization to the culprit-only strategy. The study was conducted across 34 participating sites spanning Italy, Spain, and Poland covering 1445 patients from July
Study Synopsis • The findings will impact the interventional treatment of High Bleeding Risk patients. • Data from 732 patients across 11 Dutch centres For immediate releaseSMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on innovative patient care in cardiovascular segment, today announced positive
